Number Of Medical Reports Research Articles

Phase 1/2, dose-escalation study of oral NS-018 in patients with primary myelofibrosis (PMF), post-polycythemia vera MF (post-PV MF), or post-essential thrombocythemia MF(post-ET MF)

S58 63.4% intermediate-1 63.4%, intermediate-2 28.1% and none high risk. Anemia was the most frequent laboratorial finding (67%) and most of the patients were treated with hydroxiurea (75.7%). Conclusions: Although most of the patients have apparently the diagnosis of PMF, it took almost 10 months to be done. An expressive number of medical reports do not show a complete history, while 2030% of them don’t have all the laboratory tools for a precise diagnosis. It is important to know Brazilian needs to improve diagnostic and provide a better treatment, since we are facing new drugs for PMF.

Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151

S58 63.4% intermediate-1 63.4%, intermediate-2 28.1% and none high risk. Anemia was the most frequent laboratorial finding (67%) and most of the patients were treated with hydroxiurea (75.7%). Conclusions: Although most of the patients have apparently the diagnosis of PMF, it took almost 10 months to be done. An expressive number of medical reports do not show a complete history, while 2030% of them don’t have all the laboratory tools for a precise diagnosis. It is important to know Brazilian needs to improve diagnostic and provide a better treatment, since we are facing new drugs for PMF. 806 Phase 1/2, dose-escalation study of oral NS-018 in patients with primary myelofibrosis (PMF), post-polycythemia vera MF (post-PV MF), or post-essential thrombocythemia MF(post-ET MF) Efficacy Parameter 24 weeks 36 weeks Patients with BM fibrosis reduction 1 grade 35% 50% Patients with BM fibrosis reduction by CIA 58% 90% Symptom Response 25% 27% % Change in spleen size -6% -16%

Magnesium – food and human health

In the early 21st century, as has been demonstrated by a number of medical reports, human health is seriously threatened by diseases and symptoms related to an insufficient intake of magnesium, independently of country, age and sex. The main causes are deeply rooted in the currently dominant eating habits, mostly based on cereals, i.e. on low concentration of minerals in grain. As it has been lately documented, edible parts of new, high-yielding varieties of cereals and also some vegetables (an important source of magnesium for people) are much poorer in minerals, including magnesium, than the old, lowyielding ones. Magnesium plays many important biochemical and physiological functions in plants, affecting both yield of their biomass and/or edible parts. Hence, fast growing plants require a high supply of magnesium, mainly via externally applied fertilizers, which will sustain their rate of growth. With the evidence of an insufficient content of magnesium in edible plant parts, food producers have now a new objective. Their aim is to increase the concentration of available magnesium in edible parts of plants, including both cereals and vegetables. The growing concern about low magnesium concentrations in plant products can be significantly mitigated through soil and/or foliar application of magnesium fertilizers. In order to produce magnesium-rich food, it is necessary to build up an effective strategy for magnesium management in arable soils, oriented towards providing adequate plant nutrition for sustaining normal human health. This target should be achieved when farmers apply a wide array of magnesium carriers, including fertilizers.